Insider Selling: Xencor (NASDAQ:XNCR) VP Sells $1,153,329.24 in Stock

Xencor, Inc. (NASDAQ:XNCR) VP John Desjarlais sold 73,367 shares of the company’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $15.72, for a total transaction of $1,153,329.24. Following the completion of the transaction, the vice president owned 236,574 shares in the company, valued at $3,718,943.28. This trade represents a 23.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Xencor Stock Down 0.3%

NASDAQ XNCR opened at $15.17 on Tuesday. The firm has a 50-day moving average price of $15.51 and a two-hundred day moving average price of $11.49. Xencor, Inc. has a 12-month low of $6.92 and a 12-month high of $24.66. The company has a market capitalization of $1.08 billion, a P/E ratio of -8.57 and a beta of 0.96.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.64. The company had revenue of $21.00 million during the quarter, compared to the consensus estimate of $29.73 million. Xencor had a negative net margin of 87.14% and a negative return on equity of 20.44%. The firm’s quarterly revenue was up 18.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.71) earnings per share. Equities analysts expect that Xencor, Inc. will post -3.68 EPS for the current year.

Hedge Funds Weigh In On Xencor

A number of institutional investors have recently added to or reduced their stakes in the stock. State of Wyoming acquired a new stake in Xencor in the first quarter valued at approximately $34,000. Hantz Financial Services Inc. lifted its stake in shares of Xencor by 209.1% in the 3rd quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 2,156 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Xencor by 77.1% in the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 1,449 shares during the last quarter. Farther Finance Advisors LLC acquired a new stake in shares of Xencor during the 3rd quarter valued at $44,000. Finally, Tower Research Capital LLC TRC grew its position in Xencor by 118.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 3,018 shares during the last quarter.

Analyst Ratings Changes

Several analysts have recently issued reports on XNCR shares. Bank of America lowered Xencor from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $23.00 to $12.00 in a report on Wednesday, September 3rd. Royal Bank Of Canada increased their price objective on shares of Xencor from $18.00 to $19.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Cantor Fitzgerald boosted their target price on shares of Xencor from $40.00 to $42.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Barclays upped their price target on shares of Xencor from $23.00 to $26.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Xencor from $20.00 to $18.00 and set an “overweight” rating on the stock in a research note on Thursday, November 6th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $24.88.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.